Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CEA CAR T cell therapy - Chongqing Precision Biotech

X
Drug Profile

Anti CEA CAR T cell therapy - Chongqing Precision Biotech

Latest Information Update: 16 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Precision Biotech Co., Ltd
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 06 Nov 2023 Chongqing Precision Biotech initiates a phase I trial (Late-stage disease, Recurrent, Metastatic disease, Second line therapy or greater) in China (IV, Intraperitoneal) (NCT06126406)
  • 25 Aug 2023 Chongqing Precision Biotech initiates a phase-I trial in Solid tumours (Late-stage disease, Recurrent, Metastatic disease, Second line therapy or greater) in China (IV; Intraperitoneal) (NCT06010862)
  • 25 Aug 2023 Chongqing Precision Biotech initiates a phase I/II trial in Solid tumours (Late-stage disease, Recurrent, Metastatic disease, Second line therapy or greater) in China (NCT06006390)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top